Roivant Sciences Ltd. (NASDAQ:ROIV) Director Financial Lp Qvt Sells 5,656,081 Shares

Roivant Sciences Ltd. (NASDAQ:ROIVGet Rating) Director Financial Lp Qvt sold 5,656,081 shares of the company’s stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $4.75, for a total transaction of $26,866,384.75. Following the completion of the transaction, the director now directly owns 5,470,181 shares of the company’s stock, valued at approximately $25,983,359.75. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Roivant Sciences Stock Up 2.5 %

ROIV opened at $5.29 on Tuesday. The firm has a 50-day simple moving average of $4.20 and a two-hundred day simple moving average of $4.08. Roivant Sciences Ltd. has a 52 week low of $2.52 and a 52 week high of $16.76. The company has a market capitalization of $3.72 billion, a PE ratio of -3.31 and a beta of 1.89. The company has a quick ratio of 6.20, a current ratio of 6.20 and a debt-to-equity ratio of 0.22.

Roivant Sciences (NASDAQ:ROIVGet Rating) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.18). Roivant Sciences had a negative net margin of 2,110.83% and a negative return on equity of 68.61%. The company had revenue of $4.32 million for the quarter, compared to the consensus estimate of $6.45 million. Analysts forecast that Roivant Sciences Ltd. will post -1.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Tudor Investment Corp Et Al lifted its holdings in shares of Roivant Sciences by 483.9% in the 3rd quarter. Tudor Investment Corp Et Al now owns 354,099 shares of the company’s stock valued at $1,140,000 after acquiring an additional 293,459 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Roivant Sciences by 169.8% in the 3rd quarter. Renaissance Technologies LLC now owns 227,400 shares of the company’s stock valued at $732,000 after acquiring an additional 143,100 shares during the last quarter. Two Seas Capital LP lifted its holdings in shares of Roivant Sciences by 71.6% in the 3rd quarter. Two Seas Capital LP now owns 5,869,690 shares of the company’s stock valued at $18,900,000 after acquiring an additional 2,449,854 shares during the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of Roivant Sciences by 97.4% in the 3rd quarter. Teacher Retirement System of Texas now owns 85,509 shares of the company’s stock valued at $275,000 after acquiring an additional 42,199 shares during the last quarter. Finally, Daiwa Securities Group Inc. bought a new position in shares of Roivant Sciences in the 3rd quarter valued at about $35,000. Institutional investors own 51.44% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ROIV. Citigroup upped their target price on shares of Roivant Sciences from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, August 16th. JPMorgan Chase & Co. began coverage on shares of Roivant Sciences in a report on Thursday, October 27th. They issued an “overweight” rating and a $7.00 target price for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Roivant Sciences currently has a consensus rating of “Buy” and an average price target of $10.83.

Roivant Sciences Company Profile

(Get Rating)

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.

Recommended Stories

Insider Buying and Selling by Quarter for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.